Evidence map›Paper›PMID 34370893›Full record

ArticleCurrent protocols2021

Profiling and Validation of Live-Cell Protein Methylation with Engineered Enzymes and Methionine Analogues.

Nicole Weiss, Chamara Seneviranthe, Ming Jiang, Ke Wang, Minkui Luo

Open access · greenAbstract read
In one paragraph

Article in Current protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. DNA Labeling Using DNA Methyltransferases.Advances in experimental medicine and biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nicole WeissBCMB Allied Program, Weill Cornell Medical College, Cornell University, New York, New York.
Chamara SenevirantheChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Ming JiangChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Ke WangChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Minkui LuoChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Interrogating Protein Methyltransferases with Integrated ApproachesR35GM131858 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI Minkui Luo · 2019 to 2026
$6.3M
NCI NIH HHS P30 CA008748NIGMS NIH HHS R35 GM131858NIGMS NIH HHS R35GM134878
6 · The paper itself

Abstract

Protein methyltransferases (PMTs) regulate many aspects of normal and disease processes through substrate methylation, with S-adenosyl-L-methionine (SAM) as a cofactor. It has been challenging to elucidate cellular protein lysine and arginine methylation because these modifications barely alter physical properties of target proteins and often are context dependent, transient, and substoichiometric. To reveal bona fide methylation events associated with specific PMT activities in native contexts, we developed the live-cell Bioorthogonal Profiling of Protein Methylation (lcBPPM) technology, in which the substrates of specific PMTs are labeled by engineered PMTs inside living cells, with in situ-synthesized SAM analogues as cofactors. The biorthogonality of this technology is achieved because these SAM analogue cofactors can only be processed by the engineered PMTs-and not native PMTs-to modify the substrates with distinct chemical groups. Here, we describe the latest lcBPPM protocol and its application to reveal proteome-wide methylation and validate specific methylation events. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Live-cell labeling of substrates of protein methyltransferases GLP1 and PRMT1 with lcBPPM-feasible enzymes and SAM analogue precursors Support Protocol: Gram-scale synthesis of Hey-Met Basic Protocol 2: Click labeling of lcBPPM cell lysates with a biotin-azide probe Alternate Protocol: Click labeling of small-scale lcBPPM cell lysates with a TAMRA-azide dye for in-gel fluorescence visualization Basic Protocol 3: Enrichment of biotinylated lcBPPM proteome with streptavidin beads Basic Protocol 4: Proteome-wide identification of lcBPPM targets with mass spectrometry Basic Protocol 5: Validation of individual lcBPPM targets by western blot.

Indexed as

MethionineS-AdenosylmethionineHumansMethylationProtein-Arginine N-MethyltransferasesProtein MethyltransferasesProteomeRepressor ProteinsMethioninePRMT1 protein, humanProtein-Arginine N-MethyltransferasesProtein MethyltransferasesProteomeRepressor ProteinsS-AdenosylmethionineBioorthogonal Profiling of Protein MethylationBPPMclick reactionHey-methionine analoguelcBPPMlive-cell BPPMmethyltransferasesprotein arginine methylationprotein lysine methylationS-adenosyl-L-methionine

Identifiers

PMID34370893
PMCPMC8363118
OpenAlexW3191913223

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.